drugset / Trial / NCT03540303
Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
Phase 1
Unknown
15 enrolled
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd. · collab
SequentialOpen-labelTreatment
Summary
Evaluation of the safety and efficacy of CAR19 T cells carrying cytoplasmic activated PD1 in patients with refractory relapsed B-cell lymphoma
Timeline
- Start
- 2018-04-12
- Primary completion
- 2020-04-30
- Completion
- 2020-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR19 T cells carrying cytoplasmic activated PD-1 | Unknown | 2 cells/kg | — |
| Subject | CAR19 T cells carrying cytoplasmic activated PD-1 | Unknown | 6 cells/kg | — |
| Subject | CAR19 T cells carrying cytoplasmic activated PD-1 | Unknown | 18 cells/kg | — |